Switch theme
Sign up to access all valuation multiples
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd is a Chinese bio-pharmaceutical company. It is engaged in the research development, production and sales of allergic diseases diagnosis and treatment products. The product portfolio of the company covers dust mites drops, dust mites skin prick diagnosis kit, silk, and others.
2002
n/a
LTM Revenue $136M
Last FY EBITDA $57.9M
$1.3B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Zhejiang Wolwo Bio-Pharma has a last 12-month revenue (LTM) of $136M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Zhejiang Wolwo Bio-Pharma achieved revenue of $128M and an EBITDA of $57.9M.
Zhejiang Wolwo Bio-Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Zhejiang Wolwo Bio-Pharma valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $136M | XXX | $128M | XXX | XXX | XXX |
| Gross Profit | $129M | XXX | $122M | XXX | XXX | XXX |
| Gross Margin | 95% | XXX | 95% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | $57.9M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 45% | XXX | XXX | XXX |
| EBIT | $50.5M | XXX | $46.2M | XXX | XXX | XXX |
| EBIT Margin | 37% | XXX | 36% | XXX | XXX | XXX |
| Net Profit | $45.6M | XXX | $44.1M | XXX | XXX | XXX |
| Net Margin | 34% | XXX | 34% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Zhejiang Wolwo Bio-Pharma's stock price is CNY 20 (or $3).
Zhejiang Wolwo Bio-Pharma has current market cap of CNY 10.6B (or $1.5B), and EV of CNY 9.3B (or $1.3B).
See Zhejiang Wolwo Bio-Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.3B | $1.5B | XXX | XXX | XXX | XXX | $0.09 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Zhejiang Wolwo Bio-Pharma has market cap of $1.5B and EV of $1.3B.
Zhejiang Wolwo Bio-Pharma's trades at 10.0x EV/Revenue multiple, and 22.3x EV/EBITDA.
Equity research analysts estimate Zhejiang Wolwo Bio-Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Zhejiang Wolwo Bio-Pharma has a P/E ratio of 32.1x.
See valuation multiples for Zhejiang Wolwo Bio-Pharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.5B | XXX | $1.5B | XXX | XXX | XXX |
| EV (current) | $1.3B | XXX | $1.3B | XXX | XXX | XXX |
| EV/Revenue | 9.5x | XXX | 10.0x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 22.3x | XXX | XXX | XXX |
| EV/EBIT | 25.5x | XXX | 27.9x | XXX | XXX | XXX |
| EV/Gross Profit | 10.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | 32.1x | XXX | 33.2x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 64.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialZhejiang Wolwo Bio-Pharma's last 12 month revenue growth is 15%
Zhejiang Wolwo Bio-Pharma's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Zhejiang Wolwo Bio-Pharma's rule of 40 is 60% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Zhejiang Wolwo Bio-Pharma's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Zhejiang Wolwo Bio-Pharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 15% | XXX | 15% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 45% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 60% | XXX | 60% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 23% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 13% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 59% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Zhejiang Wolwo Bio-Pharma acquired XXX companies to date.
Last acquisition by Zhejiang Wolwo Bio-Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Zhejiang Wolwo Bio-Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Zhejiang Wolwo Bio-Pharma founded? | Zhejiang Wolwo Bio-Pharma was founded in 2002. |
| Where is Zhejiang Wolwo Bio-Pharma headquartered? | Zhejiang Wolwo Bio-Pharma is headquartered in China. |
| Is Zhejiang Wolwo Bio-Pharma publicy listed? | Yes, Zhejiang Wolwo Bio-Pharma is a public company listed on SHE. |
| What is the stock symbol of Zhejiang Wolwo Bio-Pharma? | Zhejiang Wolwo Bio-Pharma trades under 300357 ticker. |
| When did Zhejiang Wolwo Bio-Pharma go public? | Zhejiang Wolwo Bio-Pharma went public in 2014. |
| Who are competitors of Zhejiang Wolwo Bio-Pharma? | Similar companies to Zhejiang Wolwo Bio-Pharma include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Zhejiang Wolwo Bio-Pharma? | Zhejiang Wolwo Bio-Pharma's current market cap is $1.5B |
| What is the current revenue of Zhejiang Wolwo Bio-Pharma? | Zhejiang Wolwo Bio-Pharma's last 12 months revenue is $136M. |
| What is the current revenue growth of Zhejiang Wolwo Bio-Pharma? | Zhejiang Wolwo Bio-Pharma revenue growth (NTM/LTM) is 15%. |
| What is the current EV/Revenue multiple of Zhejiang Wolwo Bio-Pharma? | Current revenue multiple of Zhejiang Wolwo Bio-Pharma is 9.5x. |
| Is Zhejiang Wolwo Bio-Pharma profitable? | Yes, Zhejiang Wolwo Bio-Pharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
